Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Heuser

Showing results (241-250 of 280) with videos related to

Pageof 28
Sort By:
Blood Advances|November 19, 2024
Role of molecular alterations in transplantation decisions for patients with primary myelofibrosisDamien Luque Paz, Nico Gagelmann, Lina Benajiba, et al.
Blood Advances|September 30, 2024
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurinFrank G Rücker, Lars Bullinger, Sibylle Cocciardi, et al.
Blood|May 2, 2013
Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG)Verena I Gaidzik, Richard F Schlenk, Peter Paschka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2019
Gemtuzumab Ozogamicin in <i>NPM1</i>-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III StudyRichard F Schlenk, Peter Paschka, Julia Krzykalla, et al.
Blood|September 8, 2018
Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AMLFelicitas Thol, Razif Gabdoulline, Alessandro Liebich, et al.
Leukemia|July 28, 2021
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study resultsFrank G Rücker, Ling Du, Tamara J Luck, et al.
Leukemia|July 4, 2024
Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY studyAlberto Hernández-Sánchez, Teresa González, Marta Sobas, et al.
Cancers|September 27, 2025
Prognostic Role of Kidney Disease in Newly Diagnosed Acute Myeloid Leukemia Under Venetoclax-Based Low-Intensity TherapyKatja Krüger, Razif Gabdoulline, Martin Wichmann, et al.
Leukemia|February 9, 2026
Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemiaRabea Mecklenbrauck, Angela Villaverde Ramiro, Eric Sträng, et al.
Leukemia|May 4, 2018
Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trialPeter Paschka, Richard F Schlenk, Daniela Weber, et al.
Pageof 28

Showing results (241-250 of 280) with videos related to

Sort By:
Pageof 28
Blood Advances|November 19, 2024
Role of molecular alterations in transplantation decisions for patients with primary myelofibrosisDamien Luque Paz, Nico Gagelmann, Lina Benajiba, et al.
Blood Advances|September 30, 2024
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurinFrank G Rücker, Lars Bullinger, Sibylle Cocciardi, et al.
Blood|May 2, 2013
Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG)Verena I Gaidzik, Richard F Schlenk, Peter Paschka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2019
Gemtuzumab Ozogamicin in <i>NPM1</i>-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III StudyRichard F Schlenk, Peter Paschka, Julia Krzykalla, et al.
Blood|September 8, 2018
Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AMLFelicitas Thol, Razif Gabdoulline, Alessandro Liebich, et al.
Leukemia|July 28, 2021
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study resultsFrank G Rücker, Ling Du, Tamara J Luck, et al.
Leukemia|July 4, 2024
Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY studyAlberto Hernández-Sánchez, Teresa González, Marta Sobas, et al.
Cancers|September 27, 2025
Prognostic Role of Kidney Disease in Newly Diagnosed Acute Myeloid Leukemia Under Venetoclax-Based Low-Intensity TherapyKatja Krüger, Razif Gabdoulline, Martin Wichmann, et al.
Leukemia|February 9, 2026
Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemiaRabea Mecklenbrauck, Angela Villaverde Ramiro, Eric Sträng, et al.
Leukemia|May 4, 2018
Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trialPeter Paschka, Richard F Schlenk, Daniela Weber, et al.
Pageof 28